Rationale: Uterine fibroids are the most common pelvic solid tumors and common to 25% of women.
Introduction
Uterine fibroids are the most common pelvic solid tumors and common to 25% of women. Uterine fibroids are benign tumors derived from over growth of smooth muscles and connective tissues. During the past 35 years, the incidence of uterine fibroids is as high as 30%, but only 0.2% of uterine fibroids become sarcoma. [1] 18 F-fluorodexyglucose ( 18 F-FDG) is an energy metabolism tracer. Although FDG is generally concentrated in malignant lesions with high glucose metabolism, it can also accumulate in normal tissues, benign lesions, and inflammatory sites. Lee et al [2] first reported a case of benign uterine fibroids confirmed by pathology with FDG uptake. The exact mechanism of FDG uptake by uterine fibroids is not clear but may be associated with the following factors, including hormone dependence, number of viable tumor cells, microvascular density, tumor cell proliferation, expression of growth factors (fibroblast growth factor, transforming growth factor-b, granulocyte-macrophage colonystimulating factor, Ki-67, and its receptor), glucose transporter-1, and hexokinase, as well as existence of endometrial tissues and inflammatory cells. [3] 2. Case presentation Previous written and informed consent were obtained from the patient, and this study was approved by the ethics review board of Soochow University. The patient was a 43-year-old woman and admitted to our hospital because of "1-year-extended menstrual periods." At admission, she had normal CA125, AFP, and CEA levels and CA19-9 >1000.00 U/mL. Gynecological transvaginal ultrasound found enlarged uterus with an anterior hypoechoic area of 3.9 Â 4.2 cm. Computed tomography (CT) and contrast-enhanced CT showed significantly enhanced mass shadow on the left anterior wall of the uterus (Fig. 1B,C) . 18 F-FDG positron emission tomography/computed tomography (PET/CT) showed increased FDG metabolism of tumor in the anterior wall of the uterus (Fig. 1A, D, E) . She was treated with laparoscopic hysterectomy. Intraoperational observation showed middle uterus with size as 60 days of pregnancy, obvious bulge at the left anterior wall of the uterus, and 1 uterine fibroid with size about 4.0 Â 4.0 cm, smooth endometrium, and normal bilateral tubes. Postoperational pathological examination confirmed that she had subserosal leiomyoma (Fig. 1F ). Her CA19-9 level dropped to 91.50 U/mL 1 day after surgery.
Discussion
CA19-9 is a mucus-containing macromolecule carbohydrate tumor-associated antigen mainly secreted by tumor cells in gastrointestinal tracts. It has been widely used for diagnosis and effective monitoring of gastrointestinal cancer. Tsao et al [4] found that uterine fibroids may be associated with elevated CA19-9 up to 60 U/mL. Recently, Babacan et al [5] also found that in addition increased CA125 by 19.7%, CA19-9 level also increased by 6.6% in patients with uterine fibroids, and the elevated CA19-9 level is related to the position of fibroids. In this case, the patient had CA19-9 level >1000.00 U/mL, which is extremely rare. Therefore, clinicians should consider malignancy-induced significant increase in CA19-9.
The diagnostic value of 18 F-FDG PET/CT for uterine tumors has been extensively studied previously. Negative FDG imaging could exclude the possibility of malignant leiomyosarcoma of uterine, [6] but high false positive rate makes it difficult in differential diagnosis of benign and malignant uterine tumor. [7] Nishizawa et al [3] found that the rate of positive FDG imaging is higher in premenopausal women with uterine fibroids than in postmenopausal women with uterine fibroids (10.4% vs 1.2%), especially female at an age of approximately 40 years old. This phenomenon may be related to cell richness and estrogen dependence of uterine fibroids. [8, 9] Yoshida et al [10] also believed that FDG metabolism is higher in premenopausal uterine fibroids than postmenopausal ones and slightly higher in the proliferation period of menstrual cycle than other period of the menstrual cycle. Once high metabolic FDG was found in uterine fibroids at postmenopause, possible malignancy should be considered. However, high FDG uptake cannot distinguish benign and malignant leiomyoma. Other tracers, such as 3 0 -deoxy-3 0 -18 Ffluorothymidine or 16a-18 F-fluoro-17b-estradiol, may provide more useful information. [6, 11] In this case, significantly elevated CA19-9 was positioned in the uterus by PET/CT imaging, which not only avoided unnecessary gastrointestinal endoscopy and reduced the suffering of patients, but also strengthened the operation confidence in gynecologists.
